32 h. ago Weight loss jabs do not slow Alzheimer's disease as hoped, causing firm's share prices to plummet

Novo Nordisk had hoped to repurpose semaglutide - the active ingredient in its Wegovy and Ozempic jabs - as a groundbreaking dementia treatment after seeing early encouraging signs.

Economics

35 h. ago European defence company shares fall amid Ukraine peace talk hopes; Novo Nordisk reports Ozempic fails to help with Alzheimer’s – as it happened

Rolling coverage of the latest economic and financial news, as Novo Nordisk finds its semaglutide drug fails to help in Alzheimer’s treatmentGerman business morale has unexpectedly fallen this month, as companies lose hope on a recovery of the German economy following two years of contraction.The Ifo institute has reported that its business climate index fell to 88.1 in November from 88.4 in October, weaker than expected. It’s a blow to German chancellor Friedrich Merz’s efforts to revive growth through a major spending package.“Companies have little faith that a recovery is coming anytime soon.”Like U2 sang almost 40 years ago: the German economy still hasn’t found what it’s looking for.The year 2025 has been another year of hope and disappointed optimism. A year which saw excitement and enthusiasm sparked by Germany’s unprecedented fiscal policy U-turn and its decision to invest significantly in infrastructure and defence this spring. But also a year that brought a rude awakening ...

Events

37 h. ago European defence company shares fall amid Ukraine peace talk hopes; Novo Nordisk reports Ozempic fails to help with Alzheimer’s – business live

Rolling coverage of the latest economic and financial news, as Novo Nordisk finds its semaglutide drug fails to help in Alzheimer’s treatmentGerman business morale has unexpectedly fallen this month, as companies lose hope on a recovery of the German economy following two years of contraction.The Ifo institute has reported that its business climate index fell to 88.1 in November from 88.4 in October, weaker than expected. It’s a blow to German chancellor Friedrich Merz’s efforts to revive growth through a major spending package.“Companies have little faith that a recovery is coming anytime soon.”Like U2 sang almost 40 years ago: the German economy still hasn’t found what it’s looking for.The year 2025 has been another year of hope and disappointed optimism. A year which saw excitement and enthusiasm sparked by Germany’s unprecedented fiscal policy U-turn and its decision to invest significantly in infrastructure and defence this spring. But also a year that brought a rude awakening ...

Events

38 h. ago Major Ozempic study fails as Novo Nordisk reveals lackluster results

Alzheimer's disease and other dementias affect more than 55 million people globally

Events

39 h. ago Huge blow for Alzheimer's patients as results of major Novo Nordisk trial issued

There had been hopes that the trial could have had "far-reaching implications" for Alzheimer's patients

Science

40 h. ago Novo Nordisk shares slump after drug failure in Alzheimer’s trial

Outcome is blow to one of Europe’s largest listed companies

Events

8 d. ago Price of Wegovy and Ozempic weight loss drugs slashed with certain customers saving $150 per month

A recent poll found that about half of the people who take the treatments say it was hard to afford them

Economics

2 w. ago Obesity experts point to flaw in Trump’s weight loss drug deal despite price cuts and expanded eligibility

Studies have shown that many patients regain weight after stopping the medication

Economics

2 w. ago Trump watches in horror as top executive collapses at White House press conference

Novo Nordisk executive Gordon Findlay collapsed during a press conference in the Oval Office at the White House on Thursday as President Trump watched on in horror

Events

2 w. ago Novo Nordisk executive Gordon Findlay COLLAPSES in front of Trump in Oval Office

The pharmaceutical executive was standing behind Donald Trump at a press conference announcement inside the White House for a new deal for weight-loss medications

Politics

2 w. ago Trump unveils deal to expand coverage and lower costs on obesity drugs

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy

Economics

2 w. ago Novo Nordisk cuts sales and profits guidance amid obesity drug competition

The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ever’.

Economics

2 w. ago Ozempic maker struggles as it loses ground to rivals in weight

Novo Nordisk cuts sales and profit forecasts as it continues to lose ground to Mounjaro firm Eli LillyThe maker of Ozempic and Wegovy has cut its sales and profit forecasts as it continues to fall behind in the competitive market for obesity and diabetes treatments.Novo Nordisk’s chief executive, Mike Doustdar, who took the reins in August, said the reduced guidance was because of “the lower growth expectations for our GLP-1 treatments”. Continue reading...

Politics

2 w. ago Ozempic maker Novo Nordisk cuts sales and profit forecasts again

Downgrade comes as Danish company continues to lose ground to Mounjaro firm Eli Lilly in weight-loss drug marketThe maker of Ozempic and Wegovy has cut its sales and profit forecasts as it continues to fall behind in the competitive market for obesity and diabetes treatments.Novo Nordisk’s chief executive, Mike Doustdar, who took the reins in August, said the reduced guidance was because of “the lower growth expectations for our GLP-1 treatments”. Continue reading...

Economics

3 w. ago Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies

Improved pitches from both large pharma groups expected to be revealed later on Tuesday

Events

3 w. ago Novo Nordisk and Pfizer sweeten offers for Metsera as bidding war intensifies

Big pharma groups pitted against each other in bid to improve position in growing obesity market

Events

3 w. ago Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid

Novo and Metsera deny Pfizer’s arguments

Politics

3 w. ago Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugsNovo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for dominance in the weight-loss market.The bid comes weeks after Metsera agreed to a $7.3bn takeover from the US group Pfizer. Denmark’s Novo Nordisk, which owns the weight-loss drugs Ozempic and Wegovy, lost out in a competitive auction processin September. Continue reading...

Events